Skip to main content
Log in

Formoterol

c

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 April 1998

Summary

Synopsis

Formoterol, a selective β2-adrenoceptor agonist, produces effective doseproportional bronchodilation, which persists for up to 12 hours, in patients with reversible obstructive respiratory disease. Bronchodilation is significant within minutes of inhalation, maximal within 2 hours, and at therapeutic doses is equivalent to that produced by standard doses of traditional β2-agonists. In single-dose studies comparing the two long-acting β2-agonists formoterol and salmeterol, significant broncho dilation is achieved more rapidly with formoterol than salmeterol. Duration of bronchodilation is similar with both drugs.

The therapeutic efficacy of inhaled formoterol has been equal to or greater than that of salbutamol (albuterol), fenoterol and terbutaline in both short and long term clinical trials. Formoterol reduces symptoms of nocturnal asthma and reduces the need for rescue medication compared with salbutamol. Recent studies have shown that the addition of inhaled formoterol 12 or 24μg twice daily to existing inhaled corticosteroid regimens improves lung function and reduces asthma symptoms compared with placebo. In one well designed study, the frequency of severe exacerbations of asthma over 12 months was decreased by adding formoterol to existing regimens of inhaled corticosteroids. Tolerance to the bronchodilator response of formoterol has not been observed in long term clinical trials.

Because of its long duration of action, formoterol offers significant therapeutic advantages over shorter-acting β2-agonists in the treatment of nocturnal and exercise-induced asthma. Formoterol is effective in preventing exercise-induced asthma in adults and children and confers significantly more protection than salbutamol when administered 3 and 12 hours before exercise.

In general, inhaled formoterol is well tolerated. The most commonly reported adverse effects, tremor and palpitations, are those traditionally associated with the use of β2-agonists. Oral formoterol and high doses of inhaled formoterol are associated with more adverse events than are the recommended doses of 6 to 24μg.

Formoterol is currently recommended for use as an alternative to increasing inhaled steroid dosage in patients whose symptoms are inadequately controlled despite therapy with low to moderate doses of inhaled steroids and intermittent short-acting β2-agonists, and results of recent studies support therapeutic guidelines. Long term clinical studies comparing formoterol and salmeterol have not yet been published. Further studies to evaluate the earlier use of formoterol in patients with mild to moderate asthma are needed to determine the role and long term safety of formoterol in the management of asthma.

Pharmacodynamic Properties

The long-acting selective β2-adrenoceptor agonist formoterol elicited dose-proportional bronchodilation in patients with asthma as measured by forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), and specific airways conductance (sGaw). As with salbutamol (albuterol), clinical effects of formoterol were detected within 1 minute after inhalation; however, the duration of bronchodilation with formoterol was significantly longer than with salbutamol. The onset of action of formoterol was more rapid than that of salmeterol, but the duration of effect (≈12 hours) was similar for both drugs. Formoterol usually produced maximum bronchodilation within 2 hours of inhalation. Dry powder capsule formulations of formoterol have been equipotent with formoterol administered from a metered-dose inhaler (MDI) in improving pulmonary function. Formoterol has exhibited some anti-inflammatory effects in vitro. Formoterol inhibited allergen-induced responses in animals and patients with asthma. In patients with moderate chronic obstructive pulmonary disease (COPD), the onset and duration of action of formoterol 24μg and salmeterol 50μg were similar. However, the effects of salmeterol persisted longer than those of formoterol in patients with severe COPD.

Oral formoterol produced small dose-related increases in heart rate and decreases in blood pressure but cardiovascular effects were significant only after high doses administered by inhalation. The cardiovascular effects of formoterol and salbutamol were similar, but less than those associated with fenoterol. Rebound bronchial hyperresponsiveness has not been seen after stopping treatment with formoterol. Attenuation of the bronchodilator response, with a concomitant decrease in the density of β2-receptors on peripheral blood lymphocytes, has been noted after 2 or 4 weeks of formoterol use.

Pharmacokinetic Properties

Formoterol exhibited a biphasic serum concentration after single-dose inhalation of 120μg, with an initial peak of 52 ng/L at 0.25 hours followed by a second peak of 40 ng/L at 1.58 hours. The mean plasma half-life of formoterol has been calculated as 3.4 hours after oral administration and 1.7 to 2.3 hours after inhalation.

Therapeutic Efficacy

The therapeutic efficacy of inhaled and oral formoterol has been demonstrated in both short and long term studies in patients with stable asthma or chronic obstructive airways disease. In studies that provided relevant baseline data, mean FEV1 was usually 60 to 67% of predicted value. In noncomparative and placebo-controlled trials, formoterol improved symptoms, produced clinically relevant increases in PEF and FEV1, and reduced the need for rescue medication in patients with asthma. Improvements in lung function and control of asthma symptoms with formoterol were maintained during up to 5 years of treatment; there was no evidence of a reduced bronchodilator response or worsening of asthma control. Long term studies showed no difference in lung function in patients using formoterol with or without concomitant anti-asthma therapy.

Results of comparative trials showed inhaled formoterol to be generally superior to salbutamol in improving lung function and asthma symptoms. In a representative study, formoterol 12μg twice daily was associated with a greater decrease in diurnal variation in pre-bronchodilator PEF (from 56 to 17 L/min) than salbutamol 200μg 4 times daily (from 45 to 42 L/min); morning FEV1 and PEF were higher with formoterol than with salbutamol, even though salbutamol recipients used more rescue medication. Nocturnal asthma symptoms were better controlled by formoterol than by salbutamol. As with MDIs, dry powder formulations of formoterol were at least as effective as those of salbutamol.

Formoterol 6 or 12μg twice daily via Turbuhaler® (a multidose inspiratory flow-driven dry powder inhalation device) was more effective than terbutaline 500μg 4 times daily at increasing morning and evening PEF and reducing day and night-time symptoms in studies involving more than 600 patients with stable asthma. Formoterol and fenoterol similarly improved lung function, but formoterol was more efficacious in relieving nocturnal asthma. Effects on lung function of formoterol and a combined regimen of fenoterol and ipratropium bromide were similar, but the overall efficacy of formoterol was considered to be better.

A recent well designed double-blind study demonstrated that the addition of inhaled formoterol 12μg twice daily to inhaled budesonide 100 or 400μg twice daily reduced the frequency of severe exacerbation of asthma, improved PEF and symptom control and reduced the need for β2-agonist rescue medication compared with placebo. Similarly, formoterol 24μg twice daily was more effective than placebo in improving morning PEF and asthma symptom score and reducing the need for rescue medication when added to existing therapy with inhaled corticosteroids. Initial results from a nonblind study indicate that the addition of formoterol 12μg twice daily to inhaled beclomethasone 250μg twice daily resulted in a significantly greater increase in PEF than doubling the dosage of the inhaled corticosteroid.

In asthma patients receiving regular inhaled corticosteroid therapy, improvement in quality of life after 6 months was slightly greater after the addition of formoterol 12μg twice daily via Aerolizer® inhaler (a single-dose inspiratory flow-driven dry powder inhalation device) compared with salmeterol 50μg twice daily via Diskhaler®, although this difference did not reach statistical significance.

A single dose of formoterol 12μg by inhalation provided significantly greater protection against exercise-induced asthma (EIA) than salbutamol 200 or 400μg when administered 3 to 12 hours before exercise. Postexercise FEV1 decreased by 9% (median) at 3 hours compared with 17% after salbutamol and by 8 to 11% when formoterol was inhaled 12 hours before exercise. In children, formoterol 12μg conferred about 75% protection against EIA when inhaled 3 hours before exercise, compared with the 46 and 17% protection provided by inhaled salbutamol 400 and 200μg, respectively. Similar results were obtained when dry powder capsule formulations of formoterol and salbutamol were compared in patients with EIA.

In patients with chronic obstructive airways disease, formoterol was more effective in increasing FEV1 and improving symptoms than fenoterol and salbutamol. These results need to be confirmed in long term studies.

When inhaled via Turbuhaler® significant changes in lung function compared with placebo were elicited by formoterol 6μg twice daily. However, in studies of patients using other dry powder inhalation devices, the duration of action of formoterol 6μg was less than that of formoterol 12 and 24μg.

Tolerability

All formulations of formoterol are well tolerated, with the fewest adverse events associated with inhaled formoterol. The most commonly reported adverse effects with inhaled formoterol have been tremor and palpitation, traditionally associated with the use of β2-agonists. Headache, muscle cramps, nausea and anxiety have also been reported. In long term studies in adults, the incidence of adverse events associated with inhaled formoterol ranged from 0 to 11%. Clinically significant cardiac or metabolic effects were extremely rare. Higher doses of inhaled formoterol (48μg) increased heart rate and tremor amplitude.

Formoterol has been as well tolerated as terbutaline and salbutamol in short and long term comparative studies. Elderly patients have tolerated formoterol as well as salbutamol, with no significant changes in electrocardiogram tracings, heart rate, blood pressure, or laboratory values with either drug.

Dosage and Administration

The current recommended use for formoterol is as an alternative to increasing inhaled corticosteroid dosage in patients in whom asthma symptoms are not adequately controlled with beclomethasone or budesonide 200 to 800μg daily or fluticasone 100 to 400μg daily and as-required short-acting β2-agonists. Inhaled formoterol 6 μg twice daily via Turbuhaler®, or 12μg twice daily via Aerolizer®, other dry powder devices or MDI should initially be added to the above regimen, and may be increased to 24μg twice daily if necessary. In Europe, formoterol dosage is expressed as that delivered to the patient, 4.5 to 18μg twice daily, rather than the metered dose of 6 to 24μg twice daily. Formoterol is intended as maintenance therapy and is not recommended as rescue treatment for severe exacerbations of asthma. Patients should be advised not to discontinue steroids while on formoterol therapy, although dosage adjustments may be possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42: 115–37

    Article  PubMed  CAS  Google Scholar 

  2. Maesen FPV, Costongs R, Smeets SJ. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992 May; 101: 1376–81

    Article  PubMed  CAS  Google Scholar 

  3. Ringdal N, Derom E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler (Rm) in mild to moderate asthma [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 68

    Google Scholar 

  4. Vandenberg BTJ, Smeets JJ, Vanboxtel CJ, et al. Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundam Clin Pharmacol 1995; 9(6): 593–603

    Article  CAS  Google Scholar 

  5. Maesen FPV, Smeets SJ, Costongs MAL. Onset of action of eformoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pract 1995 Nov–Dec; 49: 294–6

    PubMed  CAS  Google Scholar 

  6. Ullman A, Löfdahl C-G, Melander B, et al. Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy 1996 Oct; 51: 745–8

    Article  PubMed  CAS  Google Scholar 

  7. Wallin A, Sandström T, Rosenhall L. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993 Jun; 48: 611–4

    Article  PubMed  CAS  Google Scholar 

  8. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992 Jan; 47: 30–3

    Article  PubMed  CAS  Google Scholar 

  9. Lebecque P, Vliers S, Desaintmoulin T, et al. Response to a single dose of inhaled formoterol in asthmatic children — a double-blind randomized controlled study [in French]. Rev Mal Respir 1994; 11(1): 47–50

    PubMed  CAS  Google Scholar 

  10. Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992 Aug; 102: 535–8

    Article  PubMed  CAS  Google Scholar 

  11. Wong BJO, Kamada DH, Kolendowicz R, et al. Inhibition of allergen-induced airway and inflammatory responses by formoterol and beclomethasone [abstract]. J Allergy Clin Immunol 1992 Jan; 89: 176

    Google Scholar 

  12. CorvajaE, Giacobbe G, Girbino G. Bronchial response to salbutamol versus formoterol assessed by respiratory impedance [abstract]. Allergy 1996; 51 Suppl. 30: 79

    Google Scholar 

  13. Lötvall J, Lazer L, Persson G, et al. Formoterol Turbuhaler® has a faster onset of action but a similar duration of effect compared with salmeterol Diskhaler® at equipotent doses [abstract no. 62]. Am J Respir Crit Care Med 1996; 153 (4 Pt 2)

  14. van Noord JA, Smeets JJ, Raaijmakers JAM. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996 Aug; 9: 1684–8

    Article  PubMed  Google Scholar 

  15. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary diseases. Pulmon Pharmacol 1994 Apr; 7: 103–7

    Article  CAS  Google Scholar 

  16. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995 May; 89: 357–62

    Article  PubMed  CAS  Google Scholar 

  17. Ramsdale EH, Otis J, Kline PA, et al. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta2-agonist formoterol. Am Rev Respir Dis 1991 May; 143: 998–1001

    PubMed  CAS  Google Scholar 

  18. Beach JR, Bromly CL, Avery AT, et al. Speeds of action of formoterol and salbutamol after methacholine induced bronchoconstriction [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 96

    Google Scholar 

  19. Sovijarvi ARA, Reinikainen K, Freudenthal Y, et al. Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction — a placebo-controlled study. Respiration 1992 Sep–Oct; 59: 279–82

    Article  PubMed  CAS  Google Scholar 

  20. Malo J-L, Cartier A, Trudeau C, et al. Formoterol, a new inhaled beta-2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis 1990; 142: 1147–52

    PubMed  CAS  Google Scholar 

  21. Palmqvist M, Balder B, Löwhagen O, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta2-agonist. J Allergy Clin Immunol 1992 Apr; 89: 844–9

    Article  PubMed  CAS  Google Scholar 

  22. Wong BJ, Dolovich J, Ramsdale EH, et al. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis 1992 Nov; 146 (Pt 1): 1156–60

    PubMed  CAS  Google Scholar 

  23. Rabe KF, Jörres R, Nowak D. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993 Jun; 147 (Pt 1): 1436–41

    PubMed  CAS  Google Scholar 

  24. Zellweger JP, Pfenninger M, Ruff P, et al. 24-hour protective effect of salmeterol xinafoate (50 mcg) versus formoterol (24 mcg) against methacholine-induced bronchoconstriction in mild to moderate asthmatic patients: a randomized, double-blind, cross-over, single-dose trial [abstract]. Eur Respir J 1994; 7 Suppl. 18: 422

    Google Scholar 

  25. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993 Feb; 6: 204–10

    PubMed  CAS  Google Scholar 

  26. Burgess C, Ayson M, Rajasingham S, et al. The cardiovascular and metabolic effects of increasing doses of formoterol in patients with asthma [abstract]. Eur Respir J 1994; 7 Suppl. 18: 204

    Google Scholar 

  27. Nishikawa M, Mak JCW, Barnes PJ. Selective beta-2-agonists, salbutamol, salmeterol and formoterol down-regulate beta-2-adrenoceptor [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 483

    Google Scholar 

  28. Grove A, Lipworth BJ. Evaluation of the beta-2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996 Jan; 51: 54–8

    Article  PubMed  CAS  Google Scholar 

  29. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994 Jul; 97: 29–37

    Article  PubMed  CAS  Google Scholar 

  30. Newnham DM, Grove A, McDevitt DG. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995 May; 50: 497–504

    Article  PubMed  CAS  Google Scholar 

  31. Maesen FPV, Costongs R, Smeets JJ. The effects of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991 Jun; 99: 1367–73

    Article  PubMed  CAS  Google Scholar 

  32. McCrea KE, Hill SJ. Salmeterol, but not formoterol produces persistent cAMP accumulation in the B50 neuronal cell line [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 91

    Google Scholar 

  33. Lindberg S, Khan R, Runer T. The effects of formoterol, a long-acting beta-2-adrenoceptor agonist, on mucociliary activity. Eur J Pharmacol 1995 Oct 24; 285: 275–80

    Article  PubMed  CAS  Google Scholar 

  34. Melloni B, Germouty J. The influence on muco-ciliary function of formoterol — a new beta-agonist [in French]. Rev Mal Respir 1992; 9(5): 503–7

    PubMed  CAS  Google Scholar 

  35. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994 Mar; 7: 569–78

    Article  PubMed  CAS  Google Scholar 

  36. Waldeck B. Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists. Gen Pharmacol 1996 Jun; 27: 575–80

    Article  PubMed  CAS  Google Scholar 

  37. Butter JJ, van den Berg BTJ, Portier EJG, et al. Determination by HPLC with electrochemical detection of formoterol enantiomers in urine of healthy human subjects after single dose racemate inhalations [abstract]. Pharm World Sci 1995 May 26; 17 Suppl. D: 6

    Google Scholar 

  38. Braat MCP, Portier EJG, van den Berg BTJ, et al. Formoterol detection and pharmacokinetics in human subjects after an oral dose of 168 micrograms [abstract]. Am Rev Respir Dis 1992 Apr; 145: A60

    Google Scholar 

  39. Derks MGM, van den Berg BTJ, van der Zee JS, et al. Pharmacokinetics/pharmacodynamics of inhaled formoterol [abstract]. Neth J Med 1995 May; 46: A54

    Google Scholar 

  40. Grossman J, Busse W, Kreitzer S, et al. Double-blind, crossover trial of formoterol aerosol in patients with asthma [abstract no. P35]. In: 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology 1996: 33

  41. Kemp JP, Chervinsky P, Nelson H, et al. A randomised, double-blind, placebo-controlled, dose-response study with formoterol Turbuhaler® [abstract no. 1343]. J Allergy Clin Immunol 1997; 99 (Pt 2): S329

    Google Scholar 

  42. Häcki MA, Ritter AM, Medici TC. Long-acting beta-2-agonists: regular daily use of formoterol over five years [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 259

    Google Scholar 

  43. Shima K, Takenaka S. The clinical evaluation of formoterol (BD 40A) in bronchial asthma with long term administration and in chronic obstructive pulmonary disease with short term administration. Yakuri to Chiryo 1983; 11: 3935–42

    Google Scholar 

  44. Clauzel AM, Rifaï N, Bony C, et al. Safety of formoterol administered over 20 months in 68 severe asthmatics [abstract]. J Allergy Clin Immunol 1992 Jan; 89: 176

    Google Scholar 

  45. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992 Nov; 69: 415–20

    PubMed  CAS  Google Scholar 

  46. Steffensen I, Faurschou P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: a 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995 Aug; 50: 657–63

    Article  PubMed  CAS  Google Scholar 

  47. Maesen FPV. Longlasting treatment of stable moderately severe asthma patients with formoterol alone does not lead to desensitization [abstract]. Eur Respir J 1994; 7 Suppl. 18: 110

    Google Scholar 

  48. Maesen BLP, Smeets SJ, Costongs R, et al. Long-term effects of the beta-2-adrenoreceptor agonist formoterol for two years on lung function of stable asthmatic patients [abstract]. Chest 1993 Mar; 103 Suppl.: 286

    Article  Google Scholar 

  49. de Blic J, Kuusela AL. Formoterol dry powder capsules for inhalation in children with asthma treated over one year [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 14

    Google Scholar 

  50. Hock W, Eisele I, Hoyer H, et al. Long term effects of formoterol in patients with asthma receiving regular steroid therapy [abstract]. Eur Respir J 1992 Aug; 5 Suppl. 15: 208

    Google Scholar 

  51. Nielsen KG, Skov M, Klug B, et al. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®. Eur Respir J 1997; 10: 2105–9

    Article  PubMed  CAS  Google Scholar 

  52. Angus RM, Thomson NC, Uk ESG, et al. Comparison of the efficacy and tolerability of eformoterol and salbutamol dry powder capsules for inhalation in elderly asthmatic patients [abstract]. Thorax 1995 Apr; 50: 469P

    Google Scholar 

  53. Arvidsson P, Larsson S, Löfdahl C-G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991 Nov; 4: 1168–73

    PubMed  CAS  Google Scholar 

  54. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991 Sep; 144: 622–5

    Article  PubMed  CAS  Google Scholar 

  55. Maesen FPV, Dutch FPCG. Formoterol versus salbutamol. The Dutch 15 months study [abstract]. Chest 1995 Sep; 108 Suppl.: 209

    Article  Google Scholar 

  56. Sprogoe-Jakobsen U, Viktrup L, Davidsen O, et al. Bronchial asthma treated with long-acting beta 2 agonist: comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily [in Danish]. UgeskrLaeger 1992 Nov 16; 154: 3325–8

    CAS  Google Scholar 

  57. Stålenheim G, Wegener T, Grettve L, et al. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994 Nov–Dec; 61: 305–9

    Article  PubMed  Google Scholar 

  58. Becker AB, Lukowski JL, Simons FER, et al. Formoterol modifies chronic airway hyperresponsiveness in children with asthma [abstract]. J Allergy Clin Immunol 1991 Jan; 87 (Pt 2): 308

    Article  Google Scholar 

  59. Tsoy AN, Cheltzov VV, Zaseyeva OV, et al. Formoterol and terbutaline aerosols in nocturnal asthma. Eur Respir J 1990 Sep; 3 Suppl. 10: 418S

    Google Scholar 

  60. Ekstrom T, Ringdal N, Tukiainen P. Formoterol Turbuhaler (Rm) 12 micrograms b.i.d. improves lung function in asthmatic patients compared with terbutaline and placebo [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 157

    Google Scholar 

  61. Brusasco V, Ringdal N, Ekström T, et al. Effect of formoterol 6 micrograms b.i.d. via Turbuhaler® for 3 months in asthma: comparison with terbutaline and placebo [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 158

    Google Scholar 

  62. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997 Nov 13; 337(20): 1405–11

    Article  PubMed  CAS  Google Scholar 

  63. Van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997 Jun; 52: 535–9

    Article  PubMed  Google Scholar 

  64. Bouros D. Formoterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in adult asthmatic patients: a multicenter trial [abstract no. 0150]. Eur Respir J 1997 Sep; 10 Suppl. 25: 1s

    Google Scholar 

  65. Jones PW, Brambilla R, Till MD. Quality of life in patients treated with two long-acting β2-agonists: formoterol and salmeterol [abstract no. O158]. Eur Respir J 1997 Sep; 10 Suppl. 25: 3s

    Google Scholar 

  66. Boner AL, Spezia E, Piovesan P. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 1): 935–9

    PubMed  CAS  Google Scholar 

  67. Daugbjerg P, Nielsen KG, Skov M, et al. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercised-induced asthma in children. Acta Paediatr 1996 Jun; 85: 684–7

    Article  PubMed  CAS  Google Scholar 

  68. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992 Jun; 89: 1176–82

    Article  PubMed  CAS  Google Scholar 

  69. Patessio A, Podda A, Carone M. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. Eur Respir J 1991 Mar; 4: 296–300

    PubMed  CAS  Google Scholar 

  70. Guerin JC, Germain N, Febvre N, et al. Protective effect of formoterol on exercise-induced bronchoconstriction 10 hours after inhalation. Eur Respir J 1993 Sep; 6 Suppl. 17: 201S

    Google Scholar 

  71. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication: clinical implications of differences in effectiveness. Clin Immunother 1996 Oct; 6: 273–99

    Article  Google Scholar 

  72. Prime D, Sharma RK, Slater AL, et al. In-vitro comparison of the dose delivery characteristics of two multi-dose powder inhalers delivering long acting β2-agonists [abstract no. P1641]. Eur Respir J 1997 Sep; 10 Suppl. 25: 258s

    Google Scholar 

  73. Schreurs AJ, Sinninghe Damsté HE, de Graaff CS, et al. A dose response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients. Eur Respir J 1996 Aug; 9: 1678–83

    Article  PubMed  CAS  Google Scholar 

  74. Maesen FPV, Nakratzas G, Bantje TA. Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients. Chest 1992 Nov; 102: 1544–9

    CAS  Google Scholar 

  75. van der Molen T, Turner MO, Postma DS, et al. An international multi-centre randomised controlled trial of formoterol in asthmatics requiring inhaled corticosteroid. Eur Respir J 1995; 8 Suppl. 19: 2s

    Google Scholar 

  76. Bauer K, Sertl K, Kaik B. Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma. J Allergy Clin Immunol 1995 Oct; 96: 495–501

    Article  PubMed  CAS  Google Scholar 

  77. Eformoterol — a second long acting beta-2 agonist [editorial]. Pharm J 1996 Jan 13; 256: 52

  78. Svedmyr N, Löfdahl C-G. The use of beta2-adrenoceptor agonists in the treatment of bronchial asthma. Pharmacol Toxicol 1996 Jan; 78: 3–11

    Article  PubMed  CAS  Google Scholar 

  79. Tilles SA, Nelson HS. Long-acting inhaled beta agonists. J Asthma 1995; 32(6): 397–404

    Article  PubMed  CAS  Google Scholar 

  80. Barnes PJ, Barnett AH, Brewis RAL, et al. Guidelines for the management of asthma: a summary. BMJ 1993 Mar 20; 306: 776–82

    Article  Google Scholar 

  81. British Guidelines on Asthma Management. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: 1–20

    Article  Google Scholar 

  82. National Asthma Education and Prevention Programme. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda: NHLBI Information Center, 1997

    Google Scholar 

  83. North of EAGDG. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults. BMJ 1996 Mar 23; 312: 762–6

    Article  Google Scholar 

  84. Joint Task Force on Practice Parameters. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995 Nov; 96 (Pt 2): 707–870

    Google Scholar 

  85. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference summary of recommendations. Can Resp J 1996; 3: 89–100

    Google Scholar 

  86. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994 Jul 23; 344: 219–24

    Article  PubMed  CAS  Google Scholar 

  87. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8

    PubMed  CAS  Google Scholar 

  88. Jack D. Drug treatment of bronchial asthma 1948–1995 — years of change. Int Pharm J 1996 Mar–Apr; 10: 50–2

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rebecca A. Bartow.

Additional information

Various sections of the manuscript reviewed by: R. Dahl, Department of Respiratory Diseases, University Hospital of Aarhus, Aarhus C, Denmark; P. Daugbjerg, Department of Paediatrics, National University Hospital, Rigshospitalet, Copenhagen, Denmark; F.P.V. Maesen, De Wever-Ziekenhuis, Heerlen, The Netherlands; I. Steffensen, Department of Pulmonary Medicine, Copenhagen University Hospital Gentofte, Hillerod, Denmark; A.E. Tattersfield, Respiratory Medicine Unit, City Hospital, Nottingham, England; J.H. Toogood, Department of Allergy and Immunology, Victoria Hospital, London, Ontario, Canada.

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259988.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartow, R.A., Brogden, R.N. Formoterol. Drugs 55, 303–322 (1998). https://doi.org/10.2165/00003495-199855020-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855020-00016

Keywords

Navigation